Previous | Next
Part: 12 Session: 145678910111213141516171819202122 Page 546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598 of 999
survival in late breast cancer.
BCG comes in.
Yes, BCG is important. The Study of three drugs called CMF, which is an adjuvant study -- that is, treating immediately after the operation. It's a hard word, I think, but the doctors are all using it.
Yes, that's the current jargon.
Yes. It's treatment right after operation instead of waiting for the cancer to recur. It seems to prevent recurrence quite dramatically. In people who are treated, only 10% recur. These are people who've had a spread of the cancer to more than one node of the arm. AT 27 months about 10% recur. And in the people that are untreated, something around 30% recur. So there's a very big difference. We're looking anxiously for the figures every four or five months to see how they're holding up, because this could really reduce the death rate from breast cancer quite dramatically.
You also said some time past that it was thought it might be useful in prostate and colon cancers and that sort of thing.
© 2006 Columbia University Libraries | Oral History Research Office | Rights and Permissions | Help